For the year ending 2025-12-31, DYN had $458,349K increase in cash & cash equivalents over the period. -$405,127K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -446,214 |
| Stock-based compensation expense | 45,851 |
| Depreciation and amortization expense | 2,049 |
| Accretion of discount on marketable securities | -1,835 |
| Loss (gain) on sale of marketable securities | -30 |
| Non-cash lease expense | 163 |
| Non-cash interest expense | 118 |
| Loss on disposal of property and equipment | -95 |
| Prepaid expenses and other current assets | -986 |
| Other non-current assets | 12,641 |
| Accounts payable and other liabilities | 8,251 |
| Net cash used in operating activities | -403,207 |
| Purchases of property and equipment | 1,920 |
| Advance payment for long-lead equipment | 18,790 |
| Purchases of marketable securities | 180,534 |
| Maturities of marketable securities | 154,642 |
| Sales of marketable securities | 17,851 |
| Net cash (used in) provided by investing activities | -28,751 |
| Proceeds from issuance of common stock in public offering, net of issuance costs | 593,957 |
| Proceeds from issuance of common stock in at-the-market offering, net of issuance costs | 140,653 |
| Proceeds from exercise of stock options | 7,999 |
| Proceeds from issuance of long-term debt, net of issuance costs paid | 148,256 |
| Payment of debt issuance costs | 558 |
| Net cash provided by financing activities | 890,307 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 458,349 |
| Cash, cash equivalents and restricted cash, beginning of year | 437,391 |
| Cash, cash equivalents and restricted cash, end of year | 895,740 |
Dyne Therapeutics, Inc. (DYN)
Dyne Therapeutics, Inc. (DYN)